- Home
- AMST vs BCAB Comparison
AMST vs BCAB Comparison
Compare AMST & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMST | BCAB |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 5.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMST | BCAB |
|---|---|---|
| Price | $1.07 | $1.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 105.7K | 67.8K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | $110,459.00 | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $0.12 |
| 52 Week High | $4.78 | $6.52 |
Technical Indicators
Market Signals| Indicator | AMST | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 20.01 |
| Support Level | $0.90 | $0.17 |
| Resistance Level | $1.09 | $4.24 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 43.76 | 8.03 |
Price Performance
Historical ComparisonAbout AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.